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Objective: To develop a method for eliminating the epithelium and mixed
glands from tracheal grafts by detergent treatment and evaluate these grafts
for immunosuppressant-free allotransplantation in dogs.
Methods: Fresh canine tracheal grafts were treated with a detergent (1%
Triton X-100 t-octylphenoxypolyethoxyethanol; T-9284; Sigma Chemical
Co, St Louis, Mo) at 4°C for 48 hours. The grafts were then used for
intrathoracic 5-ring tracheal replacement in other dogs without immunosup-
pressant treatment (n = 6, detergent treatment group). In the control group (n
= 6) fresh untreated canine tracheal segments were implanted as allografts.
All the implanted grafts were covered with an omental pedicle.
Results: In the detergent treatment group the chondrocytes in the graft had a
similar appearance to those in the fresh trachea, indicating that the chondro-
cytes remained viable after the detergent treatment. In 5 of the 6 grafts, the
epithelium and mixed glands had been removed completely. After transplan-
tation, these 5 grafts were incorporated by the host trachea without stenosis.
In the remaining treated tracheal graft, in which removal of the epithelium
was incomplete, moderate stenosis was observed at the fourth week after
implantation, although this was not progressive. In the control group, granu-
lation tissue of the graft and significant stenosis were observed after trans-
plantation.
Conclusion: The antigenicity of tracheal grafts can be greatly reduced by
removing the epithelium and mixed glands by the use of detergent treatment.
The epithelium and mixed glands of the graft appear to be the determining
elements involved in rejection after tracheal allotransplantation. (J Thorac
Cardiovasc Surg 2000;120:108-14)
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antigens are those expressed by a single chromosomal
region known as the major histocompatibility complex
(MHC), which in human subjects is located on chromo-
some 6. MHC has been found to play an important role
in graft rejection.1,2
It has previously been reported that MHC-II and
MHC-I antigens are expressed in the epithelium and
mixed glands of the trachea but not in tracheal carti-
lage.3-5 This suggests that the mucosa, and not the car-
tilage, is the major antigenic structure of the trachea and
thus responsible for transplant rejection. If the anti-
genicity of tracheal grafts could be eliminated, then
immunosuppressant-free tracheal allotransplantation
could possibly be performed. We have therefore devel-
oped a detergent treatment technique that removes the
antigenic structures from tracheal grafts while main-
taining cartilage viability and used the grafts treated in
I t is widely known that recipients of allografts tend toreject them after implantation. The rejection of allo-
grafts is elicited by foreign histocompatibility antigens
on the grafted cells. Many antigens can act as histo-
compatibility antigens. The strongest transplantation
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this way for tracheal allotransplantation without
immunosuppressants.
Material and methods
Preparation of tracheal allografts. Fresh tracheal grafts,
including 7 to 8 cartilage rings, were harvested from beagle
dogs weighing 9 to 16 kg.
In the detergent treatment group the inner surface of the
graft was scraped with a plastic blade and then rinsed with
running water at room temperature. After immersion in 3.0%
saline solution for 10 minutes at 4°C, the inner surface of the
graft was scraped again. It was then immersed and stirred in
3 L of 1.0% t-octylphenoxypolyethoxyethanol solution
(Triton X-100; T-9284; Sigma Chemical Co, St Louis, Mo) at
4°C for 12 hours, and the inner surface was scraped again.
The above procedure was repeated 4 times, requiring a total
of about 48 hours. Finally, the graft was thoroughly rinsed
with physiologic saline solution to remove the detergent, and
it was stored in physiologic saline solution at 4°C until use
(storage time, 2-39 hours). A total of 6 grafts were prepared
in this way.
Histologic examination and demonstration of MHC-II
antigen. Before transplantation, one ring was resected from
each end of every graft to check the preoperative condition of
the graft by means of light microscopy and scanning electron
microscopy.
Immunohistochemical staining for MHC-II antigen was
performed by the labeled streptavidin biotin method on
frozen sections (5 µm). The primary antibody used was a rat
anti-canine MHC-II antibody (MCA 1044; Serotec, Oxford,
United Kingdom) diluted 1:50, and the secondary antibody
was a biotin-conjugated rabbit anti-rat antibody (STAR52,
Serotec) diluted 1:300. The sections were incubated with the
primary antibody at room temperature for 1 hour and then
with the secondary antibody at room temperature for 1 hour.
The horseradish peroxidase conjugated with streptavidin was
detected by means of the diaminobenzidine reaction.
Tracheal allotransplantation. After endotracheal intubation
of the recipient beagle dog (weight, 7-16 kg), anesthesia was
maintained with 50% oxygen, 50% nitrous oxide, and 1%
halothane. An omental pedicle graft was prepared and drawn
into the right hemithorax through the diaphragm, and the right
side of the chest was opened at the fourth intercostal space. A 5-
ring segment of the intrathoracic trachea was then removed, and
the defect was reconstructed with the treated graft (n = 6, deter-
gent treatment group). Telescopic anastomosis was performed
by interrupted suturing with 4-0 Prolene suture (Ethicon, Inc,
Somerville, NJ). In the control group, fresh untreated tracheal
segments were transplanted as allografts immediately after har-
vest (n = 6). The anastomotic site and the graft were wrapped
with the omental pedicle in both groups.
Postoperative care and observation. No immunosuppres-
sants were given at any time during the course of the experi-
Fig 1.  Light microscopic and scanning electron microscopic examination revealed that the epithelium and mixed glands
of the grafts had been completely removed from grafts 1 to 5 in the detergent treatment group. (A, Hematoxylin and eosin
staining, original magnification 25×; B, original magnification 2500×.) The chondrocytes in the graft appeared similar to
those in the fresh trachea.
Fig 2.  The epithelium and mixed glands are no longer seen
in grafts 1 to 5 in the detergent treatment group. No MHC-II
antigen is identified. (Original magnification 25×.) 
110 Liu et al The Journal of Thoracic and
Cardiovascular Surgery
July 2000
ment. An antibiotic (ampicillin sodium–cloxacillin sodium
for injection, 500 mg/d) was administered intramuscularly on
the day of the operation and continued daily for 1 week. The
dogs were then given ampicillin-cloxacillin tablets orally
(500 mg/d) from the second to the fourth week. Broncho-
scopic examination was performed at the second and fourth
weeks after the operation and monthly thereafter in the deter-
gent treatment group and once a week in the control group.
When the animals were killed, the implanted grafts were
removed en bloc for histologic examination.
All the animals used in this study received humane care in
compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes of
Health (National Institutes of Health publication No. 86-23,
revised 1985).
Results
In the detergent treatment group (Table I), complete
removal of the epithelium and the mixed glands was
confirmed by both light and scanning electron
microscopy in 5 of the 6 grafts (Fig 1). The appearance
of the cartilage cells was similar to that in fresh untreat-
ed trachea, indicating that the cartilage cells remained
viable. MHC-II was not identified in these grafts (Fig
2). In the remaining tracheal graft, some residual
epithelium was detected. Deformation of the remaining
epithelium was severe, and our immunohistochemical
staining system did not demonstrate expression of
MHC-II antigen. All animals (n = 6) in the detergent
treatment group survived uneventfully for more than 3
months (Table I). The observation period for 4 dogs
was more than 6 months, with the longest being 321
days. Two dogs were killed at 3 months and 3 dogs
were killed at 6 months after transplantation. Broncho-
scopic examination showed no stenosis or granulation
tissue in the grafts in dogs 1 to 5 (Fig 3). The inner sur-
face of the grafts was shiny, and the grafts had been
incorporated by the host trachea in all 5 dogs.
Macroscopically, no necrosis or atrophy was observed
in any of the grafts. Complete epithelial regeneration
was confirmed in all the implanted grafts by both light
and scanning electron microscopy. In dog 6, moderate
stenosis was detected at the fourth week after surgery,
but it did not progress any further, and the dog was
asymptomatic.
In the control group (Table II), the fresh tracheal
grafts had intact epithelium, subepithelial mixed
glands, and viable chondrocytes (Fig 4). MHC-II anti-
gen was identified in both the epithelium and the mixed
glands but not in the cartilage (Fig 5). During these
immunohistochemical staining procedures, both the
positive and negative controls clearly stained as effect-
ed, and no background or other nonspecific staining
was observed. Graft necrosis and dissolution were
observed from 2 to 3 weeks after the operation in the
control group (Fig 6). Granulation tissue gradually
began to obstruct the airway, and fatal stenosis
occurred in 3 dogs during the observation period.
Histologic examination of the grafts showed that
absorption of the tracheal cartilage was accompanied
by severe lymphocyte and monocyte infiltration into
the subepithelium.
Table II. Results in the control group
Epithelium and mixed 
No. glands on the graft Status of graft Survival (d) Cause of death
1 Intact Severe stenosis 42 Killed
2 Intact Granulation 63 Killed
3 Intact Granulation 56 Killed
4 Intact Severe stenosis 70 Killed
5 Intact Severe stenosis 35 Killed
6 Intact Granulation 63 Killed
Table I. Results in the detergent treatment group
Epithelium and mixed 
No. glands on the graft Status of graft Survival (d) Cause of death
1 Removed completely Incorporated 321 Alive
2 Removed completely Incorporated 183 Killed
3 Removed completely Incorporated 189 Killed
4 Removed completely Incorporated 191 Killed
5 Removed completely Incorporated 108 Killed
6 Epithelium remaining Moderate stenosis 91 Killed
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Discussion
Direct end-to-end anastomosis is possible when less
than 6.4 cm of the trachea has been resected.6 When
longer segments are removed, another method of recon-
struction is necessary. Tracheal transplantation has been
studied for several decades. The reasons for the lack of
success are mainly due to graft ischemia and rejection.
Anatomically, it is difficult to anastomose tracheal ves-
sels.7 Neville and colleagues8 reported that dogs could
not survive longer than 1 month with a 5-ring free tra-
cheal graft, even in the case of an autograft. The cause of
death was stenosis of the airway induced by collapse of
Fig 3.  Bronchoscopic (A, 2 weeks after transplantation; B, 6 months after transplantation) and macroscopic (C, 6
months after transplantation) findings in dog 2 in the detergent treatment group. The graft has been incorporated
by the host trachea without stenosis. Complete regeneration of the epithelium is confirmed. (D, Hematoxylin and
eosin staining, original magnification 100×.)
Fig 4.  Pseudostratified columnar ciliary epithelium and subepithelial mixed glands are observed in the fresh tra-
chea. (A, Hematoxylin and eosin staining, original magnification 25×.) Scanning electron microscopic examina-
tion reveals dense cilia covering the fresh tracheal surface. (B, Original magnification 2500×.)
the graft. For graft viability to be maintained, promotion
of graft revascularization appears to be necessary.
Messineo,9 Nakanishi,10 and their colleagues reported
that omentopexy was an effective method for facilitating
neovascularization in tracheal autografts. The trachea
was long believed to have weak antigenicity.11 However,
despite omentopexy, all the animals died of airway
obstruction between 14 and 78 days after fresh tracheal
allotransplantation.12-14 Histologic examination revealed
epithelial defects, granulation tissue with fibrosis,
mononuclear cell infiltration into the subepithelium, and
absorption of the tracheal cartilage. Beigel and Muller-
Ruchholtz15,16 tried both orthotopic and heterotopic
transplantation in rats and found that the trachea was
subject to the same immunologic laws as all other tissues
when used for transplantation. In our present control
group, similar serious airway stenosis was observed after
transplantation of fresh untreated tracheal segments.
This suggested that graft rejection occurred after fresh
tracheal allotransplantation and, accordingly, the use of
immunosuppressants was necessary to control the
immune reaction.17,18 However, use of immunosuppres-
sants has certain disadvantages, especially in patients
with malignant disease. Therefore, there have been sev-
eral attempts at immunosuppressant-free tracheal trans-
plantation.
Yokomise and colleagues12,19 succeeded in perform-
ing immunosuppressant-free tracheal transplantation
with high-dose irradiated grafts and long-term cryopre-
served grafts. Mukaida,13 Tojo,14 and their colleagues
reported that immunosuppressant-free tracheal trans-
plantation could be achieved by using cryopreserved
grafts. However, the mechanism of reduction of graft
antigenicity after cryopreservation is still unclear, and
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the question of how long a tracheal graft can be pre-
served is unanswered. With a variety of clinical needs
in mind, we considered that it is necessary to develop a
more practical method of preparing grafts.
It has long been known that cartilage can be trans-
ferred successfully between individuals of different
genetic backgrounds without any need for immunosup-
pression therapy.20 This immunologic privilege is attrib-
utable to the absence of a blood supply in adult articu-
lar cartilage. The absence of direct vascularization and
the presence of a dense proteoglycan-collagen matrix
will insulate chondrocytes from the host antigens.21
We thought that it would be difficult to eliminate the
antigenicity of tracheal allografts completely, while
maintaining their viability. However, if it were possible
to completely remove the major antigenic structures
(ie, the epithelium and mixed glands) from the graft
while maintaining the viability of the tracheal cartilage,
we thought that this graft might be successful in
immunosuppressant-free tracheal allotransplantation.
Because MHC antigen expression is observed main-
ly in the tracheal mucosa,3-5 in a preliminary experi-
ment we directly scraped the inner surface of the tra-
chea in an attempt to remove the mucosa. However, we
abandoned this method because removal of the mucosa
was inadequate and the cartilage was severely dam-
aged.
The detergent Triton X-100 is a nonionic surfactant
used to extract membrane proteins and inactivate virus-
es in human plasma.22 It converts lipids into micelles
and can destroy cell membranes, which consist of a
lipid bilayer. In this way surfactants can remove anti-
gens expressed on cell membranes, lipids, and gly-
cosaminoglycans.23,24 Yamamoto and colleagues25
reported that the use of the detergent was effective in
preparing an acellular matrix membrane from human
amnion. Sondell and colleagues26 reported the removal
of myelin and Schwann cells from nerve allografts with
Triton X-100 and application of these grafts for sciatic
nerve replacement in rats.
In the present study a 1.0% detergent solution (hypo-
tonic solution), 3.0% saline solution (hypertonic solu-
tion), and scraping were used alternately and repeated-
ly to enhance removal of the epithelium. In grafts 1 to
5 of the detergent treatment group, not only the epithe-
lium but also the subepithelial mixed glands were elim-
inated, and the viability of the chondrocytes seemed to
be maintained. Neither stenosis nor granulation tissue
occurred in the dogs that received these well-treated
grafts. Dog 6, which received a graft from which the
epithelium had not been sufficiently removed, had mild
stenosis within 4 weeks after the operation. However,
Fig 5.  MHC-II antigen is identified in the epithelium and
mixed glands of the fresh trachea (arrows; original magnifi-
cation 25×). The chondrocytes are negative.
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this stenosis did not advance thereafter. This may have
been because most of the antigenic structures had
already been removed by the detergent treatment, and
therefore the rejection was too mild to cause progres-
sive stenosis. Accordingly, we think it is important to
determine whether any residual epithelium is present
before implantation.
In this experiment the grafts containing living host
chondrocytes maintained a normal luminal shape. The
acellular matrix on the graft surface provided a site for
regeneration of the epithelium, and the regenerated
epithelium covered the inner surface of the graft.
With regard to the origin of the regenerated epitheli-
um after tracheal transplantation, Mukaida and col-
leagues,27 using polymerase chain reaction–restriction
fragment length polymorphism, concluded that the
regenerated epithelium was of recipient origin in a
cryopreserved canine tracheal allotransplantation
model. The recipient epithelium migrated gradually
from the anastomosis site to the transplanted graft and
covered the allograft within about 50 days after trans-
plantation. Tojo and colleagues28 investigated the ori-
gin of the epithelium in transplanted cryopreserved tra-
cheal allografts in rats by using immunohistochemical
staining and found that the epithelium of the trans-
planted segment originated from the recipient epitheli-
um, whereas the cartilage retained the structure of the
donor trachea 2 months after transplantation. Beigel
and colleagues29 also confirmed that the tracheal allo-
graft epithelium would be replaced by recipient epithe-
lium after transplantation.
The bulk of experimental and clinical evidence sug-
gests that cartilaginous allografts have a greater ten-
dency for late deterioration and absorption than auto-
grafts.21 The long-term changes in the cartilage of
allotransplanted tracheal tissue are still unclear.
Therefore, an additional period of observation will be
required to confirm whether malacia of the graft will
occur after transplantation.
Conclusion
We have found that the epithelium and subepithelial
mixed glands of tracheal grafts are the determining fac-
tors involved in rejection after tracheal allotransplanta-
tion. We developed a new practical method for elimi-
nating the epithelium and subepithelial mixed glands
from tracheal allografts by detergent treatment while
maintaining the viability of the chondrocytes and used
the treated grafts for successful immunosuppressant-
free tracheal transplantation.
Fig 6.  Bronchoscopic (A, 2 weeks after transplantation; B, 5 weeks after transplantation) and macroscopic (C, 5
weeks after transplantation) findings reveal serious stenosis of the graft in the control group. Lymphocyte-mono-
cyte infiltration and absorption of the tracheal cartilage are evident. (D, Hematoxylin and eosin staining, original
magnification 100×.)
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